Long-acting injections given once every two months can prevent HIV at least as well as daily pills for gay and bisexual men and transgender women, according to interim study results released May 18 by the National Institutes of Health.
A large clinical trial sponsored by the National Institute of Allergy and Infectious Diseases showed that injectable cabotegravir, an experimental integrase inhibitor from ViiV Healthcare, was 69% more effective for HIV prevention than daily Truvada (tenofovir